Comenzamos los ateneos centrales del ICBA! Mañana presentamos un caso desafiante con gran trabajo en red en 🇦🇷 con Maria José Estebanez como invitada @mestebanez144 Mostraremos el detrás de escenas del trasplante cardíaco 🎥 Los esperamos a las 13hs! Inscripción Via zoom:

🙌🙌❤️

Alguien podría pasarme el artículo de esto por favor

Top3 heart failure trials in January 2024 🥇AF in AHF: A position statement from the #ACVC and #EHRA of @escardio 🥈Integration of implantable device therapy in patients with HF. A clinical consensus statement from the #AHF and #EHRA of @escardio 🥉ARNI across EF and

⚠️⚠️Management of Worsening Heart Failure With Reduced Ejection Fraction 👉 treating congestion 👉managing precipitants 👉 establishing a foundation of rapid-sequence, simultaneous, and/or in-🏥 initiation of quadruple medical therapy 👉 consideration of upfront simultaneous use

Top3 heart failure trials in June 2023 🥇How to manage HFpEF: practical guidance for clinicians @JACCJournals 🥈Remote monitoring for HF management at home @JACCJournals 🥉HF diagnosis in the general community @ESC_Journals

#PARAGLIDE-HF trial in @JACCJournals 👉466 👥 sacubitril/valsartan vs valsartan in EF >40% enrolled within 30 days of a WHF event 👉 sacubitril/valsartan vs valsartan alone 📌led to greater ⤵️ in NT-proBNP levels 📌clinical benefit 📌 more symptomatic hypotension 📥

Defining Heart Failure Based on Imaging the Heart and Beyond via @radcliffeCARDIO 👉 Modern imaging methods enable congestion – both haemodynamic/vascular and in tissues – to be identified and quantified objectively. 📥 https://t.co/yMt2tPDv2c

💶cost-effectiveness of dapagliflozin in HFpEF/HFmrEF: A 🇬🇧🇩🇪🇪🇸 health-economic analysis of the #DELIVER trial 👉 dapagliflozin treatment was predicted to ↗️ QALYs and life-years by 0.231 and 0.354, respectively 👉 incremental cost-effectiveness ratios were 🇬🇧£7,761 🇩🇪€9,540

📝Opportunities of 💊 Initiation Among Inpatients With HFrEF 👥 50,170 from 160 site 👉 The number of 👥 receiving all indicated 💊 ↗️ from admission (14.9%) to discharge (32.8%) 👉 lower odds of HF 💊 initiation 📌 older age 📌🙋‍♀️ 📌stroke, PAD, pulmonary disease, & renal

Association of Beta-Blocker Therapy With Cardiovascular Outcomes in Patients With Stable Ischemic Heart Disease 👥 28039 stable CAD without heart failure or a recent myocardial infarction 📌The 5-year BB⤵️8%☠️all cause/HF or AMI🏥 👉AMI🏥⤵️ 13% 👉🚫no differences ☠️all cause/HF

⚠️Excelent review👇👇 Remote Monitoring for #HF Management at 🏠 via @JACCJournals 📥 https://t.co/3IOojtSG5I

⚠️A narrative review of HFpEF in breast cancer survivors 👉Increasing screening for CV risk factors (BP) 👉When BC survivors develop HFpEF, treatment focuses on initiating guideline- directed medical 💊 👉improving HFpEF prevention @Heart_BMJ @vidyogeswaran @RichardKCheng2

📝Cardio-Renal-Metabolic (CRM) Overlap, Outcomes, and Dapagliflozin in HFmrEF/HFpEF 👉 Greater CRM multimorbidity was associated with older age, higher BMI, longer-duration HF, worse health status, and ⤵️ LVEF 👉Risk of the primary outcome increased with higher CRM overlap

🔷 MODA 🇪🇸 Dapagliflozin in chronic HF and optimized therapy results: 🎯 global reverse remodeling of🫀 structure, including LA volumes and improvement in LV geometry ⬇️ NT-proBNP 📁 https://t.co/yMKD16TCn6

🧵 What not to miss at the congress #HeartFailure2023 @escardio

🇪🇸Impact of Dapagliflozin on cardiac remodeling in patients with chronic #HF #DAPA-MODA study via @DomingoPascualF #HeartFailure2023 👥 162 stable chronic heart failure receiving optimized guideline-directed therapy, except for any SGT2i ⏰180day dapagliflozin vs placebo:

Natriuretic Response to Acetazolamide in Patients With Acute Heart Failure and Volume Overload 👥 462 from the ADVOR trial 👉Allocation to acetazolamide strongly and independently predicted natriuresis with ↗️19% increase in UNa and 115 mmol 32%↗️ total natriuresis 👉A stronger

DELIVER + DAPA-HF trials 💡effects of dapagliflozin on adjudicated HF🏥 of varying complexity and hospital length of stay (LOS) 👉 dapagliflozin consistently ⤵️ HF 🏥 regardless of severity of inpatient treatment course or LOS 📥 https://t.co/zEU1MM6CPc #HeartFailure2023

📝PARAGLIDE-HF: Sacubitril/Valsartan versus valsartan on changes in NTproBNP, safety, and tolerabilit 👉 In 👥 EF>40% stabilized after recent WHF (including de novo HF), compared with Valsartan, Sac/Val greater ⤵️in NT-proBNP (through 8 Weeks)